Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, PT Merck Tbk's Enterprise Value is Rp1,259,962 Mil.
PT Merck Tbk's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was Rp395,487 Mil. Therefore, PT Merck Tbk's EV-to-EBIT ratio for today is 3.19.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, PT Merck Tbk's Enterprise Value is Rp1,259,962 Mil.
PT Merck Tbk's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was Rp403,751 Mil. Therefore, PT Merck Tbk's EV-to-EBITDA ratio for today is 3.12.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, PT Merck Tbk's Enterprise Value is Rp1,259,962 Mil.
PT Merck Tbk's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was Rp1,268,611 Mil. Therefore, PT Merck Tbk's EV-to-Revenue ratio for today is 0.99.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, PT Merck Tbk's Enterprise Value is Rp1,259,962 Mil.
PT Merck Tbk's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was Rp420,180 Mil. Therefore, PT Merck Tbk's EV-to-FCF ratio for today is 3.00.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
PT Merck Tbk (ISX:MERK) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
PT Merck Tbk's current Enterprise Value is Rp1,259,962 Mil.
PT Merck Tbk's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp395,487 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
PT Merck Tbk's current Enterprise Value is Rp1,259,962 Mil.
PT Merck Tbk's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp403,751 Mil.
PT Merck Tbk's current Enterprise Value is Rp1,259,962 Mil.
PT Merck Tbk's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp1,268,611 Mil.
PT Merck Tbk's current Enterprise Value is Rp1,259,962 Mil.
PT Merck Tbk's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp440,197 Mil.
PT Merck Tbk's current Enterprise Value is Rp1,259,962 Mil.
PT Merck Tbk's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp420,180 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Merck Tbk Enterprise Value Related Terms
PT Merck Tbk Enterprise Value Historical Data
* Premium members only.
The historical data trend for PT Merck Tbk's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:MERK vs ZTS, UTHR, VTRS: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Merck Tbk's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Merck Tbk Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Merck Tbk's Enterprise Value distribution charts can be found below:
* The bar in red indicates where PT Merck Tbk's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
PT Merck Tbk's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of Rp1,259,962 Mil mean?
PT Merck Tbk (ISX:MERK) has a Enterprise Value of Rp1,259,962 Mil as of Jul. 14, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on PT Merck Tbk and its competitors.
Is PT Merck Tbk's Enterprise Value too high?
PT Merck Tbk's current Enterprise Value is Rp1,259,962 Mil. Overall, PT Merck Tbk has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Merck Tbk's Enterprise Value compare to ZTS and UTHR?
PT Merck Tbk's Enterprise Value of Rp1,259,962 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on PT Merck Tbk and its competitors. PT Merck Tbk's current Enterprise Value is Rp1,259,962 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Merck Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Merck Tbk (ISX:MERK) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp4,944.61, compared to a current price of Rp3,760.00 — trading 24% below its estimated fair value. The current Enterprise Value is Rp1,259,962 Mil. PT Merck Tbk's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For PT Merck Tbk (ISX:MERK), the current Enterprise Value is Rp1,259,962 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Merck Tbk (ISX:MERK) Overvalued in 2026?
Based on GuruFocus' analysis, PT Merck Tbk stock appears to be undervalued.
The current stock price of Rp3,760.00 is trading 24% below its estimated GF Value™ of Rp4,944.61.
GuruFocus considers PT Merck Tbk to be Modestly Undervalued.
Key valuation signals for ISX:MERK:
Enterprise Value: Rp1,259,962 Mil
GF Value™: Rp4,944.61 vs. price of Rp3,760.00 (24% below fair value)
No single metric tells the full story. See the ISX:MERK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia. The company operates in three segments: Biopharma, Consumer Health, and Others. The company offers pharmaceutical and biological prescription medicines for colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, as well as thyroid disorders such as hypothyroidism.
84GF Score
Get the complete analysis for ISX:MERK
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:MERK has been successfully added to your 
